Problems viewing this newsletter? View it in your browser >

July 16, 2010

Dear Advocate,

We're excited to announce the release of A Cascade of Hope and Questions: Anticipating results of ARV-based HIV prevention trials--a new document in our Anticipating Results series, which is designed to help advocates prepare for the issues raised by impending results from different biomedical HIV prevention trials. This new document focuses on preparing for the upcoming data expected from trials of ARV-based prevention strategies, starting with the results of CAPRISA 004--an effectiveness study of a 1% tenofovir gel microbicide--which will be announced next week at AIDS 2010

Visit AVAC's CAPRISA 004 page ( to download A Cascade of Hope and Questions and to view additional background information on the trial.

CAPRISA 004 is the first effectiveness trial of an ARV-based prevention strategy in HIV-negative people to release results. A Cascade of Hope and Questions provides advocates with an overview of this trial's design and key aims; describes some of the other ARV-based prevention trials that will release data in the coming week; and fits these imminent announcements into the big picture of research in this arena. 

The document provides critical background for anyone following biomedical prevention research--and is a timely addition to preparations for next week's international meeting. We will be updating this report as new data emerge, so stay tuned!

The data from CAPRISA 004 will be presented at 1pm CET / 7am ET on Tuesday, July 20 at a special session, "Safety and effectiveness of 1% Tenofovir Vaginal Microbicide Gel in South African Women: Results of the CAPRISA 004 Trial". This session will be webcast at the Kaiser Family Foundation website. Also, we encourage you to join an upcoming advocates' telebriefing to discuss the results of the trial. The call will be hosted by the Global Campaign for Microbicides and will feature a trial investigator and a number of key leaders in the field to discuss the result and answer questions. It is scheduled for Wednesday, July 21 at 9 am ET/2 pm London/3 pm Vienna and Johannesburg. You must pre-register for the call ahead of time--please click here to register.

As always, please feel free to contact us with any questions or comments. 



Forward This IssueDo you know someone who might be interested in receiving this newsletter?
Forward > 

Unsubscribe You're receiving this because you signed up for our newsletter. Not interested any longer?
Unsubscribe > 

Contact Us T: +1 212 796 6423